The Cross-Border Biotech Blog

Q4Annual2015PART2_SharePricePerformance-01

  In this blog, I am going to comment on the Q4 and 2015 annual performance of the Tier 2 group of 49 companies with share prices of between $0.10 and $0.99 to start 2015. IMRIS (taken private after a Chapter 11 filing), Premier Diagnostic Health Services (which no longer has a healthcare focus) and […]

read more


Q4Annual2015PART2_SharePricePerformance-01

  Tier 1 Companies The annual chaos of the J.P. Morgan Healthcare Conference is ongoing in San Francisco as I write this blog. Over ninety per cent of the people are not actually invited to the conference but have meetings in area hotels from dawn until the cocktail parties start. All areas of healthcare are […]

read more


Apollo_Part1

On being unintentionally non-adherent I wonder how many of us have included “better adherence to my prescription drugs” in our list of New Year’s resolutions? The answer is likely near zero. It doesn’t even make health.com’s list of the Top 10 Healthiest New Year’s Resolutions, yet study after study concludes that the negative impact of […]

read more


Q4PART1_SharePricePerformance-01

Ninety-nine Canadian healthcare companies started 2015 with share prices of $0.10 or higher. Four of these companies are no longer part of this sector, including Catamaran which was acquired by UnitedHealth Group and IMRIS which was taken private by Deerfield. For the remaining 95 companies, the sector performance in 2015 can be described by the […]

read more


BBB_Part16_Logo

Some Market Data (1) The global pharmaceutical market should hit $1 trillion in 2015. In this blog, I will highlight some public data on sales by product and therapeutic category. All of this information is from IMS Health, which makes some top-line market data available free on its website. Some of my thoughts on this […]

read more


Q3PART2_SharePricePerformance-01

Tier 2 companies lost all previous 2015 gains in Q3 In this blog, I am going to comment on the Q3 and 9-month performance of the Tier 2 group of 50 companies with share prices of between $0.10 and $0.99 to start 2015. IMRIS, taken private after a Chapter 11 filing, and Premier Diagnostic Health […]

read more


ThinkingBeyondBorder

Canada continues to be one of the world’s leaders in developing and fostering scientific breakthroughs. While talent is in great abundance in Canada, there’s been an evolution in the ways Canadian science is being commercialized and financed globally. 2014 was a year for the record books. According to EY’s 29th annual biotechnology industry report, Beyond […]

read more


Q3_2015_Part1_Title_InPost

From herd movement up in Q1 to selective movement in Q2 to herd movement down in Q3 Ninety nine Canadian healthcare companies started 2015 with share prices of $0.10 or higher. Three of these companies are no longer part of this sector, including Catamaran which was acquired by UnitedHealth Group and IMRIS which was taken […]

read more


Moday,

  Welcome to your resumed Monday Biotech Deal Review! We’re happy to announce the return of the Monday Deal Review following a brief hiatus where we were making some changes to the back end of the blog. Today’s post covers all the deal activity from the week of September 21st up to the current date. […]

read more